The FDA cleared expanded first-line use of Gilead’s antibody-drug conjugate Trodelvy (sacituzumab govitecan) for triple-negative breast cancer, adding label breadth that puts the drug in direct competitive focus versus other frontline ADCs. The new approval extends Trodelvy’s positioning within treatment lines where efficacy and tolerability are being closely differentiated. Regulators granted the update for adult patients with hormone receptor–negative and HER2–negative advanced or metastatic breast cancer, with the broader label designed to capture a wider set of patients starting treatment earlier. The move follows a separate FDA approval cycle that also moved other ADC competitors into the first-line mix. For Gilead, the label expansion increases commercial headroom and may influence treatment sequencing in clinical practice as oncologists weigh ADC scheduling alongside standard chemo and emerging combinations. For the broader ADC market, the update reinforces how quickly label expansions are shaping competitive dynamics in breast cancer.